Gender aspects in chronic myeloid leukemia: long-term results from randomized studies

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Gender-related differences in chronic myeloid leukemia (CML) are under-researched.
• Understanding these differences is crucial for personalized treatment strategies in CML.

Purpose of the Study:

• To investigate gender-specific aspects and their impact on clinical presentation, treatment response, and survival in patients with Philadelphia chromosome/BCR-ABL-positive CML.
• To analyze data from large-scale, randomized German CML studies to identify significant gender-related disparities.

Main Methods:

• Analysis of 856 patients with Ph/BCR-ABL-positive CML from German randomized CML-studies I and II.
• Median observation time of 8.6 years.
• Comparison of clinical characteristics, risk profiles, transplantation rates, and survival between male and female patients, including matched-pair analyses.

Main Results:

• Female patients were older, presented with lower hemoglobin, higher platelet counts, smaller spleen size, fewer cytogenetic aberrations, and a less favorable risk profile.
• Despite a lower transplantation rate, female patients had a significantly longer median survival (58 vs. 49 months).
• Improved survival in females was observed in low- and intermediate-risk groups and independently in the hydroxyurea (HU) treatment arm.

Conclusions:

• This study provides the first analysis of gender aspects in CML using randomized trials, demonstrating significant differences in presentation and outcomes.
• Gender is a relevant factor in CML, influencing survival and treatment response.
• The findings underscore the importance of considering gender in the management of CML and other malignant diseases.